SEC Form 4 · accession 0001628280-26-061944
Telix Pharmaceuticals Ltd · TLX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Darren Charlton Smith
Officer — Group Chief Financial Officer
Period of report
Sep 7, 2026
Accepted (ET)
Sep 14, 2026 · 7:20 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0002007191
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary SharesF1,F2 | Sep 7, 2026 | P | 2,071 | $9.656 | A | 13,992 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents shares purchased by the Reporting Person under the Employee Share Purchase Plan section of the Issuer's Equity Incentive Plan ("AU ESPP"), which shares were allocated on September 7, 2026, based on the Reporting Person's contributions to the AU ESPP from January 1, 2026 - June 30, 2026.
- F2Purchase price is recorded in Australian Dollars.